Survodutide

Buy Survodutide 10mg: Research-Grade Dual GCGR/GLP-1R Agonist

Looking to buy Survodutide 10mg for your lab? Sino Research Peptide Manufacturer supplies Survodutide with >99% HPLC-verified purity, batch-specific COA, and fast dispatch for laboratory and in-vitro research use only.

What Is Survodutide?

Survodutide, also known as BI 456906, is a 29-amino acid synthetic peptide developed by Boehringer Ingelheim, derived from glucagon with the incorporation of potent GLP-1 receptor activity. It contains a C18 diacid chain that mediates albumin binding, extending its plasma half-life to support once-weekly dosing in research models.

What distinguishes Survodutide from other compounds in this class is its dual receptor engagement — simultaneously activating both the glucagon receptor (GCGR) and the GLP-1 receptor (GLP-1R). This dual mechanism allows researchers to study two complementary and reinforcing pathways at once: GLP-1R agonism reduces appetite and food intake, while GCGR agonism increases energy expenditure and promotes fat metabolism in the liver. Together, this creates a more potent metabolic effect than GLP-1 receptor agonism alone.

Survodutide currently sits in Phase 3 clinical trials (the SYNCHRONIZE programme), making it one of the most clinically well-validated research peptides currently available.

How Does Survodutide Work?

Survodutide functions through balanced co-agonism of two key metabolic receptors.

GLP-1 Receptor (GLP-1R) Activation

• Suppresses appetite and reduces caloric intake through central satiety signalling
• Slows gastric emptying, prolonging the sensation of fullness
• Promotes insulin secretion in a glucose-dependent manner
• Reduces post-meal glucose excursions

Glucagon Receptor (GCGR) Activation

• Increases energy expenditure through hepatic and thermogenic pathways
• Promotes fatty acid oxidation and lipolysis in the liver
• Increases circulating FGF21, a metabolic hormone linked to fat burning and insulin sensitivity
• Upregulates liver NNMT mRNA expression, a validated biomarker of GCGR engagement
• Adds a catabolic energy-expenditure component absent in GLP-1 mono-agonists such as semaglutide

The result is a compound that addresses both sides of the energy balance equation in research models — reducing intake via GLP-1R and increasing expenditure via GCGR — making it one of the most mechanistically complete metabolic research tools available.

Survodutide Benefits in Research Applications

In pre-clinical and clinical research models, Survodutide has demonstrated a broad range of metabolically significant effects:

• Superior body weight reduction — Phase 2 data demonstrated mean bodyweight reductions approximately 5× greater than placebo at 4.8 mg weekly over 46 weeks, with over half of participants reaching ≥15% bodyweight reduction
• Outperforms semaglutide comparisons — Phase 2 results for Survodutide (18.7% bodyweight reduction at 4.8 mg weekly) positioned it above approved GLP-1 mono-agonist benchmarks in research comparisons
• Pre-clinical obesity models — in diet-induced obese (DIO) mice, Survodutide achieved 25% bodyweight reduction from baseline over 28 days at 30 nmol/kg
• Glycaemic control — demonstrated significant HbA1c reduction in Phase 2 trials in people with type 2 diabetes, comparable to selective GLP-1R agonism, while also achieving clinically meaningful bodyweight loss
• Liver and MASLD models — GCGR agonism is specifically studied in metabolic-associated steatotic liver disease (MASLD) and MASH models, where glucagon receptor activation has demonstrated anti-steatotic properties
• Cardiovascular research — the ongoing SYNCHRONIZE-CVOT Phase 3 trial investigates cardiovascular outcomes in adults with obesity and established cardiovascular disease or chronic kidney disease — a first for a dual GCGR/GLP-1R agonist at this trial scale
• Energy expenditure pathway research — FGF21 and NNMT upregulation are confirmed as validated in vivo biomarkers of GCGR engagement, offering researchers reliable pharmacodynamic readouts

What Do Studies Say About Survodutide?

Survodutide carries one of the most robust published research profiles of any compound in its class.

Landmark Phase 2 Trial

A randomised, double-blind, placebo-controlled trial across 43 centres in 12 countries examined adults with BMI ≥27 kg/m² without diabetes. Survodutide at 4.8 mg once weekly produced mean bodyweight reductions approximately 5× greater than placebo over 46 weeks, with more than half of participants achieving ≥15% bodyweight reduction.

Reference: le Roux CW et al. (2024). The Lancet Diabetes & Endocrinology, 12(3): 162–173. DOI: 10.1016/S2213-8587(23)00356-X

Pharmacological Profiling Study

This study confirmed Survodutide’s balanced dual GCGR/GLP-1R pharmacology, demonstrating 25% bodyweight reduction in DIO mice over 28 days, significant glucose tolerance improvement (54% AUC reduction versus vehicle), and confirming FGF21 and NNMT mRNA as validated GCGR engagement biomarkers.

Reference: Thomas L et al. (2024). Diabetes, Obesity and Metabolism, 26(6): 2368–2378. DOI: 10.1111/dom.15551

Mechanistic Review

This review confirmed Survodutide’s derivation from glucagon with incorporated GLP-1 activity and albumin-binding C18 diacid for extended half-life, reviewing Phase 2 HbA1c and bodyweight data in type 2 diabetes populations.

Reference: Klein T et al. (2024). Diabetes Research and Clinical Practice, 207: 110779. DOI: 10.1016/j.diabres.2023.110779

Discovery and Pre-Clinical Pharmacology Paper

This paper confirmed robust anti-obesity efficacy in multiple pre-clinical models and established the pharmacological rationale for dual GCGR/GLP-1R agonism as a research approach distinct from GLP-1 monotherapy.

Reference: Zimmermann T et al. (2022). Molecular Metabolism, 66: 101633.

Systematic Review and Meta-Analysis

A systematic review and meta-analysis of 18 treatment arms (1,029 participants) confirmed significant reductions in bodyweight (WMD: −8.33 kg), BMI (WMD: −4.03 kg/m²), and waist circumference (WMD: −6.33 cm) following Survodutide versus control. Longer interventions (>16 weeks) and higher doses (>2 mg/week) associated with greater reductions.

Reference: Meta-analysis (2024). Diabetology & Metabolic Syndrome. DOI: 10.1186/s13098-024-01501-x

SYNCHRONIZE-CVOT (Ongoing Phase 3)

This global cardiovascular outcomes trial targets 4,935 participants with obesity and established cardiovascular or chronic kidney disease, with a primary endpoint of time to first MACE (5-point composite) — the first Phase 3 cardiovascular safety study of a dual GCGR/GLP-1R agonist at this scale.

Reference: JACC: Heart Failure. NCT06077864. DOI: 10.1016/j.jchf.2024.09.004

Note: Phase 2 and Phase 3 clinical trial data relate to pharmaceutical development research. Survodutide is not approved for medical or therapeutic use. All supply from Sino Research Peptide Manufacturer is for in-vitro and laboratory research use only.

What Is Survodutide Used For in Research?

Researchers sourcing Survodutide typically focus on:

• Dual GCGR/GLP-1R receptor binding, activation, and co-agonism studies
• Obesity and metabolic syndrome pre-clinical and in-vitro models
• Energy expenditure and fatty acid oxidation pathway research
• Type 2 diabetes and glycaemic control investigation
• Liver steatosis, MASLD, and MASH model studies
• Cardiovascular metabolic risk and cardiac energy metabolism research
• FGF21 and NNMT as pharmacodynamic biomarkers of GCGR engagement
• Comparative dual agonist research alongside tirzepatide, mazdutide, and pemvidutide
• Structure–activity relationship (SAR) studies within the incretin mimetic class
• Chronic kidney disease and cardiometabolic risk interaction studies

Survodutide vs Other Metabolic Research Peptides

Survodutide’s unique GCGR engagement makes it the preferred research tool when studying the hepatic and energy expenditure components of metabolic disease — components that GLP-1 mono-agonists don’t fully address.

Quality and Purity Assurance

Every batch of Survodutide from Sino Research Peptide Manufacturer is:

• 99% pure — HPLC and mass spectrometry verified

• Supplied with a full Certificate of Analysis (COA) on request
• Lyophilised powder for maximum stability and long shelf life
• Manufactured under strict, controlled laboratory conditions
• Consistent batch-to-batch quality for reproducible research results

Where to Buy Survodutide 10mg Online

Survodutide for Sale

If you’ve been searching for Survodutide for sale, Sino Research Peptide Manufacturer offers HPLC and MS-verified material with full COA documentation per batch — no need to search “Survodutide peptide near me,” since we ship directly to your lab.

Where to Buy Survodutide 10mg

Wondering where to buy Survodutide 10mg? Our streamlined ordering process gets research-grade material to your lab quickly, with fast, tracked dispatch and competitive pricing, including bulk research discounts for larger orders.

Best Place to Shop Survodutide 10mg

When you source Survodutide (BI 456906) from Sino Research Peptide Manufacturer, you receive 99% purity verified by HPLC and MS, third-party tested, with full COA documentation per batch and consistent quality trusted by researchers across multiple regions.

Research Disclaimer

All products supplied by Sino Research Peptide Manufacturer are intended strictly for in-vitro laboratory research and scientific study use only. They are not intended for human consumption, veterinary use, or any medical or therapeutic application. Survodutide (BI 456906) is an investigational compound currently in Phase 3 clinical trials and has not been approved by any regulatory authority for human use.

All research citations on this page relate to pre-clinical studies, clinical trial data published for scientific purposes, and peer-reviewed pharmacological research. They do not constitute a claim of safety or therapeutic efficacy. Sino Research Peptide Manufacturer accepts no liability for any misuse of research compounds. By purchasing, you confirm that you are a qualified researcher and that the product will be used solely within a controlled laboratory environment in compliance with all applicable laws, regulations, and institutional guidelines.

References:

1. Grosicki, M., Latacz, G., Szopa, A., Cukier, A., & Kieć-Kononowicz, K. (2014). The study of cellular cytotoxicity of argireline – an anti-aging peptide. Acta biochimica Polonica, 61(1), 29–32. Buy Survodutide 10mg
2. Blanes-Mira, C., Clemente, J., Jodas, G., Gil, A., Fernández-Ballester, G., Ponsati, B., Gutierrez, L., Pérez-Payá, E., & Ferrer-Montiel, A. (2002). A synthetic hexapeptide (Argireline) with antiwrinkle activity. International journal of cosmetic science, 24(5), 303–310. https://doi.org/10.1046/j.1467-2494.2002.00153.x 
3. Raikou, V., Varvaresou, A., Panderi, I., & Papageorgiou, E. (2017). The efficacy study of the combination of tripeptide-10-citrulline and acetyl hexapeptide-3. A prospective, randomized controlled study. Journal of cosmetic dermatology, 16(2), 271–278.Buy Survodutide 10mg https://doi.org/10.1111/jocd.12314
4. An, J. H., Lee, H. J., Yoon, M. S., & Kim, D. H. (2019). Anti-Wrinkle Efficacy of Cross-Linked Hyaluronic Acid-Based Microneedle Patch with Acetyl Hexapeptide-8 and Epidermal Growth Factor on Korean Skin. Annals of dermatology, 31(3), 263–271Buy Survodutide 10mg. https://doi.org/10.5021/ad.2019.31.3.263
5. Wang, Y., Wang, M., Xiao, X. S., Pan, P., Li, P., & Huo, J. (2013). The anti wrinkle efficacy of synthetic hexapeptide (Argireline) in Chinese Subjects. Journal of cosmetic and laser therapy : official publication of the European Society for Laser Dermatology, Advance online publication. Buy Survodutide 10mg
6. Wang, Y., Wang, M., Xiao, X. S., Huo, J., & Zhang, W. D. (2013). The anti-wrinkle efficacy of Argireline. Journal of cosmetic and laser therapy : official publication of the European Society for Laser Dermatology, 15(4), 237–241. https://doi.org/10.3109/14764172.2013.769273
7. Lungu, C., Considine, E., Zahir, S.,Buy Survodutide 10mg Ponsati, B., Arrastia, S., & Hallett, M. (2013). Pilot study of acetyl hexapeptide-8 in the treatment for blepharospasm in patients receiving botulinum toxin therapy. European journal of neurology, Buy Survodutide 10mg20(3), 515–518. https://doi.org/10.1111/ene.12009
8. Palmieri, B., Noviello, A., Corazzari, V., Garelli, A., & Vadala, M. (2020). Skin scars and wrinkles temporary camouflage in dermatology and oncoesthetics: focus on acetyl hexapeptide-8. La Clinica terapeutica, 171(6), e539–e548.Buy Survodutide 10mg https://doi.org/10.7417/CT.2020.2270
9. Ponsati, B., Carreño, C., Curto-Reyes, V., Valenzuela, B., Duart, M. J., Van den Nest, W., Cauli, O., Beltran, B., Fernandez, J., Borsini, F., Caprioli, A., Di Serio, S., Veretchy, M., Baamonde, A., Menendez, L., Barros, F., de la Pena, P., Borges, R., Felipo, V., Planells-Cases, R., … Ferrer-Montiel, A. (2012). An inhibitor of neuronal exocytosis (DD04107) displays long-lasting in vivo activity against chronic inflammatory and neuropathic pain. The Journal of pharmacology and experimental Buy Survodutide 10mg therapeutics, 341(3), 634–645. https://doi.org/10.1124/jpet.111.190678
10. Butrón, D., Zamora-Carreras, H., Devesa, I., Treviño, M. A., Abian, O., Velázquez-Campoy, A., Bonache, M. Á., Lagartera, L., Martín-Martínez, M., González-Rodríguez, S., Baamonde, A., Fernández-Carvajal, A., Ferrer-Montiel, A., Jiménez, M. Á., & González-Muñiz, R. (2021). DD04107-Derived neuronal exocytosis inhibitor peptides: Evidences for synaptotagmin-1 as a putative target. Bioorganic chemistry, 115, 105231 Buy Survodutide 10mg. https://doi.org/10.1016/j.bioorg.2021.105231